Royalty Pharma Raises 2026 Guidance as Royalty Receipts Jump 14%
RPRX sits 72% above its 52-week low of $34.081.
Summary
Royalty Pharma raised its full-year 2026 Portfolio Receipts guidance to $3.4–$3.5 billion, up from $3.325–$3.45 billion, driven by a 14% jump in Q2 Royalty Receipts to $768 million. Key growth drivers include Tremfya, Voranigo, Imdelltra, and Evrysdi. Adjusted EBITDA rose to $736 million from $633 million, though net income fell to $18 million from $32 million due to non-cash charges. The raised outlook signals stronger-than-expected royalty performance, and shares edged up 1.17% pre-market. This follows a recent 8-K filing this morning with preliminary Q2 figures and the guidance raise.
At the time of this announcement, RPRX was trading at $58.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.1B. The 52-week trading range was $34.08 to $60.44. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.